NASDAQ : HRTX
Heron Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.2944 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 55.89M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 52.72M |
| Enterprise Value | 158.41M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 189.85M |
| Shares Outstanding | 189.85M |
| Shares Change (YoY) | +20.47% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 1.01% |
| Owned by Institutions (%) | 48.02% |
| Float | 146.51M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.35 |
| Forward PS | 0.69 |
| PB Ratio | 8.98 |
| P/TBV Ratio | 9.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.49 |
| Quick Ratio | 1.44 |
| Debt / Equity | 21.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.76 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -2.80% |
| Return on Invested Capital (ROIC) | -4.46% |
| Return on Capital Employed (ROCE) | -6.79% |
| Weighted Average Cost of Capital (WACC) | 9.04% |
| Revenue Per Employee | $1.18M |
| Profits Per Employee | -$266,008 |
| Employee Count | 128 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.70 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.62 |
| 52-Week Price Change | -76.26% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 0.70 |
| Relative Strength Index (RSI) | 37.09 |
| Average Volume (20 Days) | 2,043,567 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 36.74M |
| Short Previous Month | 46.02M |
| Short % of Shares Out | 19.35% |
| Short % of Float | 25.08% |
| Short Ratio (days to cover) | 14.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 151.18M |
| Gross Profit | 93.63M |
| Operating Income | -10.86M |
| Pretax Income | -34.05M |
| Net Income | -34.05M |
| EBITDA | -8.73M |
| EBIT | -10.86M |
| Loss Per Share | -$0.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 42.66M |
| Total Debt | 148.35M |
| Net Cash | -105.69M |
| Net Cash Per Share | -$0.56 |
| Equity (Book Value) | 6.91M |
| Book Value Per Share | 0.03 |
| Working Capital | 137.70M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -11.61M |
| Capital Expenditures | -529,000 |
| Depreciation & Amortization | 2.13M |
| Net Borrowing | -12.76M |
| Free Cash Flow | -12.14M |
| FCF Per Share | -$0.06 |
Margins
| Measure | Value |
|---|
| Gross Margin | 61.93% |
| Operating Margin | -7.19% |
| Pretax Margin | -22.52% |
| Profit Margin | -22.52% |
| EBITDA Margin | -5.78% |
| EBIT Margin | -7.19% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -20.47% |
| Shareholder Yield | -20.47% |
| Earnings Yield | -66.35% |
| FCF Yield | -23.02% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 1.20% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 13, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -9.21 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |